NeVa Retrospective Comparative SR Study

NITRO is a multicenter, retrospective, comparative, non-inferiority, cohort study designed to compare NeVa SR with Control SR for safety and effectiveness when removing thrombus in subjects presenting with acute ischemic stroke (AIS) due to large vessel occlusion (LVO). The objective of the NeVa International, Multi-center, Retrospective Comparative stent retriever (SR) study (NITRO) study is to compare safety and effectiveness of the NeVa SR to commonly used SR with CE-mark, and US FDA clearance, to restore blood flow in patients experiencing acute ischemic stroke due to large intracranial vessel occlusion. NITRO aims to collect data describing real-world clinical practices when using SRs according to their indicated use within the indicated population. As such, the eligibility criteria define patients who are diagnosed with AIS and are indicated for endovascular MT aligning to the target population for the proposed device. The present study will include data from subjects treated with either NeVa SR or one of the Control SR. Control SR will include any SR commonly used in thrombectomy trials as first-line strategies and which represent CE-mark, and US FDA cleared stent retrievers.

Inclusion criteria

• Treatment during the enrollment period
• Age ≥18
• Baseline modified Thrombolysis in Cerebral Infarction (mTICI) score ≤ 1
• Pre-stroke modified Rankin score (mRS) of 0 or 1
• Internal Carotid Artery (ICA), Middle Cerebral Artery (first segment M1/ second segment M2), basilar artery or vertebral artery occlusion
• National Institutes of Health Stroke Scale (NIHSS) score ≥ 8 and ≤ 25
• Thrombectomy procedure initiated within 8h of Time Last Known Well (TLKW)
• Intravenous Tissue Plasminogen Activator (IV-tPA) failed, given within 3h of TLKW, or ineligibility for thrombolytic drug

Exclusion criteria

• First line contact aspiration alone or non-study device as first-line device